ORIC Stock — Oric Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$12.85

Market cap

$1,331.9M

Cash

$264.8M

Enterprise value

$1,067.1M

Balance sheet

Cash	$264.8M
Debt	$0.0M
Net cash	$264.8M
Enterprise value	$1,067.1M
Basic shares	103.6M shares
Fully diluted shares	127.8M shares
Fully diluted market cap	$1,642.3M
Cash per share	$2.56

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading ORIC daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	ORIC-114	Phase 1/2	Solid Tumors	—
Jan 12 - Feb 23	ORIC-114 Dose 1	Phase 1	Solid Tumors; EGFR Exon 20 Insertion Mutations; NSCLC	—
Jul 13 - Aug 24	ORIC-944	Phase 1	Metastatic Prostate Cancer	—
Apr 12 - May 24	Rinzimetostat	Phase 3	Metastatic Castration Resistant Prostate Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

rinzimetostat

Phase 3 · Active Modality: small molecule (allosteric inhibitor)

Aliases ORIC-944

Target PRC2 (EED subunit)

Partnerships Mirati Therapeutics (licensed rights); Bayer (darolutamide supply for Himalayas-1, July 2026); Johnson & Johnson (apalutamide supply for Phase 1b combo)

Indications

metastatic castration-resistant prostate cancer (mCRPC) (Phase 3)

Catalysts

— July 2026

Status note Allosteric inhibitor of PRC2 via the EED subunit, designed for superior properties vs EZH2 inhibitors. RP3D selected March 2026: 400 mg QD rinzimetostat + darolutamide in mCRPC patients previously treated with abiraterone. Himalayas-1 Phase 3 initiated July 2026.

enozertinib

Phase 1 · Active Modality: small molecule (brain-penetrant, orally bioavailable, irreversible inhibitor)

Aliases ORIC-114

Target EGFR

Partnerships Voronoi Inc. (licensed development and commercialization rights)

Indications

non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion and PACC mutations (Phase 1)

Status note Being evaluated in Phase 1b trials in EGFR exon 20 insertion and P-loop/alpha C-helix compressing (PACC) mutated NSCLC, allowing enrollment of patients with treated or untreated asymptomatic CNS metastases.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Rinzimetostat
Lead indication	Metastatic Castration Resistant Prostate Cancer
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07723248	Phase 3	Recruiting	Sponsor	ORIC Pharmaceuticals	—	Metastatic Castration Resistant Prostate Cancer	—
NCT05315700	Phase 1/2	Recruiting	Sponsor	ORIC Pharmaceuticals	—	Solid Tumors	—
NCT06816992	Phase 1	Recruiting	Sponsor	ORIC Pharmaceuticals	JNJ	Solid Tumors; EGFR Exon 20 Insertion Mutations; NSCLC	—
NCT05413421	Phase 1	Recruiting	Sponsor	ORIC Pharmaceuticals	—	Metastatic Prostate Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for ORIC Pharmaceuticals on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	2,015,000	-678,929	0.41%	2026-08-14
Braidwell LP	1,214,540	+86,500	0.49%	2026-08-14
Sphera Biotech	752,983	+215,355	1.17%	2026-08-14
Logos Global Management	0	-950,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ORIC — Oric Pharmaceuticals Inc.